We are operating with a high degree of care as we protect our patients, customers and employees during this unprecedented and difficult time.
We believe it is our responsibility to prioritise two things:
- Our commitment to supporting the health and safety of our patients, customers and employees
- Protecting our ability to manufacture and supply medicines, vaccines and consumer products for patients
Consistent with our values and role as a science-led global healthcare company, we will continue to make decisions informed by the latest science and in consultation with leading health authorities. We are implementing a variety of measures to ensure the health and well-being of our patients, our customers, our employees and our communities.
Ensuring medicine supply and access
We are closely monitoring all parts of our supply chains, proactively developing contingency plans to help us respond to the situation. We have taken a number of measures to support supply of our products, including: prioritising medically critical products; building capacity to respond faster to unpredictable demand in some of our key consumer healthcare products; and working with logistics service providers to find alternative distribution routes. We are experiencing some delays with distribution and delivery of our products to customers as countries around the world introduce different virus containment measures, such as border closures and flight suspensions. Our focus is to avoid or minimise any potential delivery delays or disruptions, closely monitor what is happening and keep our customers informed.
We are closely monitoring all parts of our supply chains, proactively developing contingency plans to help us respond to the situation.
We have taken a number of measures to support supply of our products, including: prioritising medically critical products; building capacity to respond faster to unpredictable demand in some of our key consumer healthcare products; and working with logistics service providers to find alternative distribution routes.
We are experiencing some delays with distribution and delivery of our products to customers as countries around the world introduce different virus containment measures, such as border closures and flight suspensions.
Our focus is to avoid or minimise any potential delivery delays or disruptions, closely monitor what is happening and keep our customers informed.
As the situation varies in each country, please contact your local community or hospital pharmacy to see what options they are able to provide.
This may be an option for certain medicines. Please contact your treating doctor regarding this possibility.
For questions or concerns about our products, vaccines, and/or product availability, please contact us.
Patient Assistance Programs
We’ve always viewed patient support as an important part of our mission in the US, and this includes our program to help patients afford their GSK medicines. By answering a few questions, patients will be guided to a patient assistance program that may help save money on out-of-pocket costs for medicines or vaccines. For eligibility, information about our patient assistance programs, coupon and co-pay programs, reimbursement support and links to helpful government resources, visit GSKforyou.com.
Conducting clinical trials
Our priority is the safety and well-being of those who support and participate in our clinical trials and our employees. We have issued guidance to clinical trial investigators and we are implementing proactive measures to protect the safety of study participants, staff at our clinical trial sites and our employees while ensuring regulatory compliance and the scientific integrity of our clinical trials.
Our priority is the safety and well-being of those who support and participate in our trials and our employees. As such, we are implementing proactive measures to protect the safety of study participants, staff at our clinical trial sites and our employees while ensuring regulatory compliance and the scientific integrity of our clinical trials.
At this time, GSK remains supportive of enrolling new patients into ongoing clinical studies, provided that investigators are confident they will be able to conduct the protocol specified safety and efficacy monitoring required for each study.
There may be exceptional cases that require GSK to pause individual trial enrollment. Such decisions will be taken on a case by case basis considering the therapeutic area and the patient population involved in the clinical study.
For new clinical trials, and as appropriate, GSK will delay study initiation and re-evaluate as the situation evolves.
For clinical trials for vaccines, given the specific benefit / risk considerations pertinent to clinical trials with prophylactic vaccines, GSK has decided to pause recruitment of additional trial participants on a country by country basis until further notice as we continuously assess the evolving COVID-19 situation.
Please contact your study doctor who will be able to provide guidance on your participation in the study.
All GSK sponsored COVID-19 clinical studies can be found on ClinicalTrials.gov.
Caring for our people and communities
We are taking several measures to protect the well-being of our employees and the communities in which we operate. We are moving to virtual interaction approaches to ensure we can continue to support the patient community with resources and planned educational programs as appropriate.
Supporting STEM education at home
We are supporting teachers and parents to help bring STEM (science, technology, engineering, and mathematics) to life for students away from the classroom. This summer, our Science in the Summer program will be virtual. We’re showcasing at-home experiments where children aged 7-13 take on the role of four different chemists at home to solve real-world problems: medicinal chemist, materials chemist, water chemist, and color chemist. Resources include introductory videos, virtual research team meetings with The Franklin Institute educators. Explore the details about our Science in the Summer program.
Contributing to the fight against COVID-19
Since the outbreak, we have been actively exploring ways to help, with our science and expertise, alongside protecting the health and wellbeing of our people and managing our global supply chains to support patients and consumers who depend on our products.
We are collaborating with companies and research groups across the world working on promising COVID-19 vaccine candidates through the use of our innovative vaccine adjuvant technology. In addition to vaccines, we are also supporting screening and research into potential medicines for COVID-19.
Visit our COVID-19 response and updates page for updated information about our actions to fight COVID-19.
Building knowledge
Our GSK scientists are studying antibodies from survivors giving us insight to how our immune system defends us.
A complex challenge
Racing to develop a COVID-19 vaccine, we're working with scientific partners around the world.
Helping frontline health workers and offering expertise
We have initiated a new volunteering processes for people working at the company, to enable those with medical expertise to provide support to frontline health workers, while at the same time ensuring we protect supply and development of our medicines and vaccines. Initiatives have also been started to use salesforce personnel to help with delivery of PPE and testing equipment, and for specialists, such as procurement leaders, to work with national governments on developing supply chains.
We have made donations to support the dedicated front-line health workers fighting COVID-19 around the world.
- $10 million to WHO and UN Foundation’s COVID-19 Solidarity Response Fund
- $7.5 million in local donations in 29 countries
- Over $400,000 PPE units donated in 22 countries and lab equipment and kits given to support government testing
- $250,000 to Direct Relief to support ongoing emergency response efforts in our local communities
